Tagged with China

Pharma Legal Handbook A comprehensive guide to the legal implications around product liability in China. Prepared in association with Fangda Partners, one of China’s most prestigious and well-regarded law firms. This is an extract from The Pharma Legal Handbook: China, which can be purchased here for GBP 119.   1. What types of liability…

Pharma Legal Handbook An outline of the legal situation around patents and trademarks for pharmaceuticals in China. Prepared in association with Fangda Partners, one of China’s most prestigious and well-regarded law firms. This is an extract from The Pharma Legal Handbook: China, which can be purchased here for GBP 119.   1. What are…

Pharma Legal Handbook The key facts about regulatory reforms in Chinese pharma. Prepared in association with Fangda Partners, one of China’s most prestigious and well-regarded law firms. This is an extract from The Pharma Legal Handbook: China, which can be purchased here for GBP 119.   1. Are there proposals for reform or…

Pharma Legal Handbook Cannabinoid drugs, medicinal cannabis & opioid drugs in India – a comprehensive legal overview. Prepared in association with Fangda Partners, one of China’s most prestigious and well-regarded law firms. This is an extract from The Pharma Legal Handbook: China, which can be purchased here for GBP 119.   CANNABINOID DRUGS 1. Are…

Pharma Legal Handbook An intro to the legal situation for orphan drugs and rare diseases in China. Prepared in association with Fangda Partners, one of China’s most prestigious and well-regarded law firms. This is an extract from The Pharma Legal Handbook: China, which can be purchased here for GBP 119.   1. What is…

Pharma Legal Handbook Want to know more about localization in China? Prepared in association with Fangda Partners, one of China’s most prestigious and well-regarded law firms. This is an extract from The Pharma Legal Handbook: China, which can be purchased here for GBP 119.   1. Are there any rules or regulations requiring and/or encouraging…

The Pharma Legal Handbook Key legal info on biosimilars & biologics in China. Prepared in association with Fangda Partners, one of China’s most prestigious and well-regarded law firms. This is an extract from The Pharma Legal Handbook: China, which can be purchased here for GBP 119.   1. Are biosimilar medicines considered the same as generic…

China DIA Global Forum’s annual review of new drug approvals in China has shown growth in both the number and types of new drugs approved in China from 2019 through 2021: from 34 new chemical drugs and 19 biological products in 2019 to 37 new chemical drugs and 24 biological products…

China A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR deal with SciClone Pharmaceuticals.   Moderna holds onto its vaccine IP and refuses tech transfer in China (Financial Times) Moderna…

China Despite the impact of the COVID-19 pandemic and the vagaries of the country’s restrictive ‘dynamic zero COVID’ policy, the Chinese pharmaceutical industry is expected to continue its remarkable trajectory up to 2025 with annual growth of 9.4 percent. Read on for five key trends to watch out for in the…

China The top 10 Chinese pharma companies for 2022, ranked by sales value and based on data from the latest Forbes Global 2000 ranking. Big conglomerates like Sinopharm, Shanghai Pharmaceuticals, and Jointown dominate the list, while other national champions in the midst of expanding their innovation efforts like Jiangsu Hengrui and…

China China healthcare and life sciences news. Top stories include the NMPA approvals of CanSino’s inhaled COVID-19 vaccine and AstraZeneca’s CKD treatment, HitGen/Unison’s anti-infectives deal and the funding secured by cell therapy biotech Neukio Biotherapeutics.   Neovii & Fosun Pharma sign deal to bring transplantation medicine to China (BioSpectum Asia) Switzerland-based…